LONDON, December 17 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global clinical research organization (CRO) providing clinical development and staffing services in Europe, the Americas and Asia, is pleased to announce our collaboration with Dr Nawab Qizilbash of OXON Epidemiology.
Dr Nawab Qizilbash, MBChB BSc MRCP (UK) MSc Phil (Oxon) is the Director of OXON Epidemiology Ltd. He served as Director of Epidemiology and Evidence-based Medicine at GlaxoSmithKline. Formerly an Honorary Consultant Physician/Senior Research Fellow at Radcliffe Infirmary, Oxford University, Nawab trained under Professor Sir Richard Peto F.R.S. in epidemiology, Phase IV trials and meta-analysis. He also collaborates with Professor Stephen Evans in academic research on statistical signal detection. Dr Qizilbash has authored 5 publications in the Lancet, 1 in the Journal of the American Medical Association and 1 in the British Medical Journal, among others. He founded the Cochrane Dementia Group and is chief editor of an international textbook on clinical dementia.
Jane Turner, MRPharmS, Chiltern's Late Phase Director, Europe, stated, We are delighted to announce the alliance between Chiltern Late Phase and Dr Nawab Qizilbash and his company, OXON Epidemiology Ltd. OXON is a niche consultancy company that specializes in 'real world data': epidemiology, risk management and health economics. This partnership will allow Chiltern to provide epidemiology and outcomes research expertise in conjunction with flexible and bespoke late phase study solutions to our sponsors. Steve Albrecht, Global head of Chiltern Late Phase, added, We are excited about this ongoing collaboration which significantly strengthens Chiltern's global service offering in epidemiology, pharmacoeconomics and risk management.
Dr Qizilbash commented, OXON is delighted to be collaborating with Chiltern Late Phase. The combination provides scientific strength with breadth and global reach to late phase, allowing for strategic consulting, planning and implementation of: observational studies, risk management, health economics and Phase IV trials.
Company profile
About Chiltern:
Established in 1982, Chiltern is a leading global clinical Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1,400 people in 29 countries. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.
For More Information: Natalie Chong, Chiltern International Ltd. 171 Bath Road Slough, Berkshire SL1 4AA, UK Tel: +44-(0)1753-512-000 Email: natalie.chong@chiltern.com Sue Ojanen, Chiltern International Inc. 1241 Volunteer Parkway Bristol, TN 37620, USA Tel: +1-423-968-9533 Email: sue.ojanen@chiltern.com
SOURCE: Chiltern
CONTACT: Natalie Chong of Chiltern International Ltd.,+44-(0)-1753-512-000, natalie.chong@chiltern.com, or Sue Ojanen of ChilternInternational Inc., +1-423-968-9533, sue.ojanen@chiltern.com
Comments